Cizutamig (CND-106) is a bispecific T-cell engager targeting BCMA and CD3. Cizutamig exhibits immunostimulatory and anti-tumor activities. Cizutamig can be used in research related to relapsed or refractory multiple myeloma and systemic lupus erythematosus [1].
In Vivo, Cizutamig (0.5 mg/kg; intravenous administration; single dose) induces transient T cell margination, persistent B cell depletion, and mild transient cytokine induction in healthy cynomolgus monkeys[1].
In Vitro, Cizutamig exhibits binding affinity to BCMA-expressing myeloma cell lines comparable to that of T cell engagers (TCEs), while its binding affinity to CD3-positive Jurkat T cells is lower than that of the benchmark BCMA×CD3 TCE[1].
References:
[1]. Tan P, et al. POS1141 CND106, a novel BCMA-directed T-cell engager (TCE), has a differentiated safety profile and potential for development in autoantibody-driven autoimmune diseases. Annals of the Rheumatic Diseases, 2025, 84: 1217.
In Vivo, Cizutamig (0.5 mg/kg; intravenous administration; single dose) induces transient T cell margination, persistent B cell depletion, and mild transient cytokine induction in healthy cynomolgus monkeys[1].
In Vitro, Cizutamig exhibits binding affinity to BCMA-expressing myeloma cell lines comparable to that of T cell engagers (TCEs), while its binding affinity to CD3-positive Jurkat T cells is lower than that of the benchmark BCMA×CD3 TCE[1].
References:
[1]. Tan P, et al. POS1141 CND106, a novel BCMA-directed T-cell engager (TCE), has a differentiated safety profile and potential for development in autoantibody-driven autoimmune diseases. Annals of the Rheumatic Diseases, 2025, 84: 1217.